General description
We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1H18 is a ZooMAb® recombinant rabbit monoclonal antibody that specifically detects SALL4. It targets an epitope within 25 amino acids from the C-terminal region.
Immunogen
KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal region of human SALL4.
Application
Quality Control Testing
Evaluated by Western Blotting in lysate from NTERA-2 cells.
Western Blotting Analysis (WB): A 1:1,000 dilution of this antibody detected SALL4 in lysate from NTERA-2 cells.
Tested Applications
Western Blotting Analysis: A 1:50,000 dilution from a representative lot detected SALL4 in lysate from NCCIT cells and human testis and mouse testis tissues.
Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected SALL4 in Caco-2 cells.
Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected SALL4 in human testis tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Sal-like protein 4 (UniProt: Q9UJQ4; also known as Zinc finger protein 797, Zinc finger protein SALL4) is encoded by the SALL4 (also known as ZNF797) gene (Gene ID: 57167) in human. Sal-like protein 4 is a Transcription factor belongs to the spalt-like protein family with a key role in the maintenance and self-renewal of embryonic and hematopoietic stem cells. SALL4 is characterized with a multiple zinc finger (ZnF) domains including one N-terminal C2HC-type ZnF and seven C2H2-type ZnF domains. SALL4 is primarily localized in the nucleus, consistent with its function as a transcription factor. In vertebrates, its found in testis, thyroid gland and is abundantly expressed in both embryonic and adult stem/stem-like cells. The expression is tightly regulated, as inappropriate expression is associated with developmental abnormalities and cancer. It is suggested to play a role in the pathogenesis of leukemia stem cells and is reported to be constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. It has some role in All-trans retinoic acid (ATRA)-based regimes in case of leukemia therapy. Additionally, aberrant expression of SALL4 is linked to various cancers, gastric cancer, hepatocellular cancer (HCC) and colorectal cancer (CRC), where it supports the proliferation and survival of cancer cells, often correlating with a poor prognosis. It may also act as a biomarker for HCC. SALL4 plays a crucial role in the maintenance of pluripotency and self-renewal in embryonic stem cells. It interacts with other key pluripotency factors, such as OCT4 and NANOG, forming regulatory networks essential for stem cell function. Defects in this SALL4 gene are a known cause of a rare genetic disorder Okihiro/Duane-radial ray syndrome (DRRS), which involves limb and heart defects, among other symptoms. The mutation or dysfunction of the SALL4 gene leads to this developmental syndrome, underscoring its importance in normal embryonic development. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Kohlhase, J., et al. (2005) Hum Mutat. Sep;26(3):176-83).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.